Claim Missing Document
Check
Articles

Found 2 Documents
Search

Edukasi Pemanfaatan dan Pembuatan Produk Minuman Bawang Dayak Tanaman Khas Kalimantan Untuk Penyakit Degeneratif Di SMA Negeri 12 Pontianak Ressi Susanti; Clara Ritawany Sinaga; Enggy erwansani
Jurnal Pengabdian Masyarakat Farmasi : Pharmacare Society Vol 5, No 2 (2026)
Publisher : State University of Gorontalo

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37905/phar.soc.v5i2.35464

Abstract

Kalimantan memiliki keanekaragaman hayati yang luar biasa, salah satunya adalah tanaman Bawang Dayak (Eleutherine palmifolia), yang dikenal memiliki potensi tinggi sebagai obat tradisional untuk membantu pencegahan dan penanganan penyakit degeneratif seperti diabetes, tekanan darah tinggi, dan gangguan jantung. Pemahaman generasi muda, khususnya siswa di SMAN 12 Kota Pontianak, terhadap tanaman ini masih sangat minim. Tujuan dari Kegiatan PKM iniuntuk memberikan edukasi mengenai khasiat Bawang Dayak sebagai tanaman obat khas daerah serta mendorong penggunaannya secara tepat dan berkelanjutan. Metode yang digunakan dalam pengabdian ini adalah penyuluhan dan demonstrasi. Pelaksanaan kegiatan dilakukan melalui penyuluhan edukatif, sesi diskusi, pelatihan pembuatan minuman herbal siap seduh, serta pengukuran pemahaman siswa dengan pre-test dan post-test. Berdasarkan hasil evaluasi yang dilakukan, diperoleh nilai rata-rata pre-test sebesar 72,24, sedangkan nilai rata-rata post-test meningkat menjadi 80,08. Hal ini menunjukkan adanya kenaikan sebesar 7,84 poin atau peningkatan sekitar 10,85% pengetahuan setelah peserta mengikuti kegiatan edukasi. Kegiatan Pengabdian kepada Masyarakat (PkM) ini memberikan kesimpulan bahwa kegiatan bukan hanya sekadar memberi informasi, tetapi untuk mencetak kader kesehatan muda yang melek akan potensi lokal. Capaian utama yang diharapkan adalah terwujudnya komunitas belajar di SMAN 12 Kota Pontianak yang menjadi pelopor (pioneer) dalam pemanfaatan Bawang Dayak. Dengan demikian, kegiatan ini diharapkan mampu memicu sebuah gerakan sadar kesehatan yang memadukan ilmu pengetahuan modern dengan kearifan lokal Kalimantan Barat
Clinicopathologic Characteristics, Pathological Response and Safety Profile of Triple-Negative Breast Cancer (TNBC) Patients: A Retrospective Study in Yogyakarta Rommy; Clara Ritawany Sinaga; Annafiatuzakiah
Duta Pharma Journal Vol. 6 No. 1 (2026): Duta Pharma Journal
Publisher : Universitas Duta Bangsa Surakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.47701/hy4h0v48

Abstract

Background: Triple-negative breast cancer (TNBC) is a uniquely aggressive molecular subtype associated with poor prognosis, high proliferation rates, and significant genomic instability. Objective: This study aimed to determine the clinicopathologic characteristics, pathological response, and safety profile of TNBC patients in a local clinical setting. Method: A retrospective cohort study was conducted on 50 female patients at a private hospital in Yogyakarta (2019–2022). Chemotherapy regimens were categorized into platinum-based (carboplatin and taxane) and non-platinum-based (anthracycline-taxane, capecitabine, or methotrexate) groups. Pathological complete response (pCR) was defined as the total absence of residual invasive carcinoma in both the breast tissue and sampled regional lymph nodes (ypT0/Tis ypN0). Data were extracted from medical records and analyzed using bivariate statistical tests. Results: The mean age was 48.48 years (95% CI: 46.24–50.72), with 76% of patients aged 40-59. Most patients presented with cT2 tumor size (38%) and cN0 nodal status (58%). The mean Ki67 index was 24.96 (95% CI: 19.29–30.63), with 44% of patients exhibiting high proliferation (? 30%). The overall pCR rate was 20% (10/50). The platinum group achieved a higher numerical pCR rate (25%, 6/24) compared to the non-platinum group (15.4%, 4/26), though the difference was not statistically significant (OR = 1.833, 95% CI: 0.448–7.511, p = 0.490). A high Ki67 index (? 30%) was significantly associated with superior pCR achievement (OR = 7.428, 95% CI: 1.365–40.413, p = 0.014). Adverse drug reactions (ADRs) occurred in 66% (33/50) of patients, predominantly chemotherapy-induced nausea and vomiting (22%) and neurological disorders (20%). Conclusion: High Ki67 expression was associated with therapeutic response in this cohort. No statistically significant difference in pCR or total ADR incidence was observed between regimens in this sample. The study is limited by its single-center design and small sample size (n=50)